New testable hypothesis: "Zero-knowledge proofs of geospatial provenance assertions (e.g., 'this image was taken within 10km of a clinical trial site') can be integrated with federated transcriptomic datasets to enable privacy-preserving validation of spatial correlations between environmental exposures and MS-associated gene expression (e.g., CTSS pathway activity) without revealing raw loca
New testable hypothesis: *"Zero-knowledge proofs of geospatial provenance assertions (e.g., 'this image was taken within 10km of a clinical trial site') can be integrated with federated transcriptomic datasets to enable privacy-preserving validation of spatial correlations between environmental exposures and MS-associated gene expression (e.g., CTSS pathway activity) without revealing raw loca
Adversarial Debate Score
65% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- RAFT-UP: Robust Alignment for Spatial Transcriptomics with Explicit Control of Spatial Distortion
Spatial transcriptomics (ST) profiles gene expression across a tissue section while preserving the spatial coordinates. Because current ST technologies typically profile two-dimensional tissue slices,...
- M³-Gen: Interpretable Multimodal Generation of Gene Expression Profiles Using Clinical and Imaging Data
Integrating heterogeneous biomedical data, including clinical metadata, histopathology images, and molecular profiles, is crucial for comprehensive disease understanding. However, gene expression data...
- SNPgen: Phenotype-Supervised Genotype Representation and Synthetic Data Generation via Latent Diffusion
Polygenic risk scores and other genomic analyses require large individual-level genotype datasets, yet strict data access restrictions impede sharing. Synthetic genotype generation offers a privacy-pr...
- Quantifying Memorization and Privacy Risks in Genomic Language Models
Genomic language models (GLMs) have emerged as powerful tools for learning representations of DNA sequences, enabling advances in variant prediction, regulatory element identification, and cross-task ...
- TRACE-CTI: Auditable Post-Extraction Governance of TTP Claims with Knowledge Graphs
Security Operations Centers increasingly rely on automated mapping of Cyber Threat Intelligence reports to MITRE ATT&CK, yet extractor outputs remain fallible and are often stored without the evidence...
Computational Result
An LLM's reading of the literature — not computational verification.
Integration of zero-knowledge proofs with transcriptomic data is plausible but faces significant challenges.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
A zero-knowledge proof (ZKP) protocol can attest that a biospecimen/metadata record originated within a bounded geographic region (e.g., "within 10km of clinical trial site X" or "within an EPA-defined pollution exposure zone") — verifiable by a third party with cryptographic soundness ≥99.99% (false-accept rate) and completeness ≥99% — while the verifier learns nothing about the exact coordinates beyond membership in the disclosed region (statistical distinguishability advantage <0.01 between true and simulated proof transcripts). Further, this ZKP-gated geolocation attribute can be joined with federated transcriptomic pipelines (e.g., CTSS/DNMT1/ZNF740 expression from GSE193770/GSE138614-style cohorts) such that a spatial correlation analysis (e.g., regional pollution index vs. CTSS log2FC) computed over ZKP-verified-but-location-hidden records produces effect estimates within 10% relative error of the same analysis computed with raw disclosed coordinates, on a synthetic/held-out ground-truth dataset.
- Proof soundness failure: an adversarial prover can construct a valid ZKP for a false location claim with probability >10^-4 across 10,000 adversarial trials.
- Privacy leakage: a verifier or colluding third party can reconstruct the true coordinates (or narrow to <10km precision beyond the stated region) with >5% success rate above baseline guessing, measured via a distinguishing/membership-inference attack.
- Statistical distortion: the ZKP-gated correlation coefficient (region-hidden) deviates from the raw-coordinate correlation by >10% relative error, or changes significance at α=0.05 in >1/20 bootstrap resamples.
- Non-scalability: circuit compilation + proof generation exceeds 60 seconds per record on commodity hardware (16-core CPU, no GPU) at n=10,000 records, making federated deployment impractical.
- Biological null: if used as a downstream validation of CTSS, failure to detect the expected exposure-CTSS association in ANY analysis mode (raw or ZK-hidden) at effect size ≥ the GSE138614 replicated estimate (log2FC 0.673–1.16) constitutes disproof of the use-case (though not of the cryptographic method itself).
Spine & Adversarial ReadReady for validation
“This hypothesis tests whether a zero-knowledge proof of geospatial region membership can replace raw coordinate disclosure in a federated transcriptomic analysis without changing the statistical conclusion of a spatial gene-expression correlation by more than 10%.”
- highThe biological substrate (CTSS/ZNF740/DNMT1 as MS targets) is entirely unreplicated internal analysis with no external peer review, and this EVP risks laundering cryptographic novelty by attaching it to unvalidated biology — the ZK method should be validated independently of any specific gene-expression claim.Partially addressed: the protocol explicitly separates cryptographic/statistical validation (synthetic data, steps 1-9) from any biological claim, and DEPENDENCIES lists CTSS/DNMT1/ZNF740 replication as prerequisites for the real-pilot phase only. However, the EVP does not fully resolve why CTSS specifically (vs. any other spatially-varying biomarker) was chosen as the motivating example beyond narrative convenience — this should be reframed as method-first with CTSS as one of several possible test cases.
- highWhy zero-knowledge proofs specifically, rather than simpler, cheaper privacy techniques (differential privacy on coordinates, k-anonymity spatial cloaking, secure multi-party computation, or trusted execution environments) that are already well-established in federated health data literature? The methodology justification for ZKPs over these alternatives is not stated.Gap acknowledged, not resolved. ZKPs offer a unique property (cryptographic soundness of a *provenance claim* — proving the location predicate is true — rather than merely obscuring it), which DP/k-anonymity do not provide since they don't verify the claim's truthfulness. This distinction (verification vs. obfuscation) should be made an explicit comparison arm in the protocol (Step 3.5, not currently included): benchmark ZKP against DP-noised coordinates and secure-aggregation MPC on the same synthetic dataset to demonstrate the utility/privacy/verifiability tradeoff empirically rather than asserting ZKP superiority a priori.
- mediumThe statistical fidelity target (relative error <10%) is compared only against a synthetic ground truth with a single injected effect size (r=0.3); real MS-exposure correlations may be much weaker (CTSS log2FC 0.67-1.16 is a modest expression effect, not necessarily reflecting a strong spatial exposure correlation), making the region-binning privacy tradeoff potentially unworkable at real effect sizes.Not resolved — the protocol should add a power-analysis sub-study varying injected effect size (r = 0.1 to 0.5) and region granularity to map the actual usable operating range before claiming general success, since a single r=0.3 synthetic benchmark is insufficiently conservative for a modest real-world effect.
Experimental Protocol
Minimum Viable Test (MVT): A two-arm synthetic-data benchmark.
- Arm A (ground truth): Simulate N=5,000 synthetic patient records with (lat/lon, simulated CTSS expression value drawn from a model calibrated to GSE138614 effect sizes + spatial exposure gradient with known ground-truth correlation r=0.3).
- Arm B (ZK-gated): Same records, but location replaced by a ZKP attestation of "within region R_i" for 20 predefined regions; raw coordinates withheld from the analysis engine.
- Compute Pearson/Spearman correlation and mixed-effects regression (CTSS ~ exposure_proxy + region_random_effect) in both arms; compare coefficients, CIs, and p-values.
- Separately run cryptographic benchmarks: proof generation time, verification time, proof size, soundness/completeness under fuzzing (10,000 malicious proof attempts with off-region coordinates).
- Synthetic geospatial-transcriptomic cohort (generated in-house, N=5,000–20,000 simulated patients) calibrated on GSE138614 CTSS effect sizes (log2FC 0.673–1.16) and public environmental exposure layers (EPA AQS air quality data, satellite-derived pollution indices).
- GSE193770, GSE108000, GSE138614 (real transcriptomic data, for effect-size calibration only — these datasets do NOT contain real patient geolocation and cannot be used for the spatial-privacy test directly; a synthetic geo-layer must be grafted on).
- A ZKP framework/toolkit: circom + snarkjs (Groth16), or Halo2 (no trusted setup), or gnark (Go, fast prover).
- Federated learning/analytics simulation environment: Flower, PySyft, or custom MPI-based federation across ≥3 simulated "sites."
- GTEx v10 (for any tissue-expression cross-referencing of CTSS, ancillary only).
- Soundness: false-accept rate <10^-4 over 10,000 adversarial trials.
- Privacy: membership-inference/reconstruction AUC ≤0.55 (near-chance) against the ZK-gated pipeline.
- Statistical fidelity: relative error between Arm A and Arm B correlation/regression coefficients <10%; p-value significance calls concordant in ≥95% of bootstrap resamples.
- Performance: proof generation <5s/record, verification <100ms/record, total pipeline overhead <2x the raw-coordinate pipeline at N=10,000.
- Federation robustness: results stable (coefficient drift <15%) across 3–5 simulated heterogeneous sites with dropout up to 20%.
- Any soundness failure rate >10^-3 in adversarial testing → cryptographic disproof.
- Reconstruction AUC >0.65 → privacy disproof.
- Relative statistical error >20% or discordant significance calls in >10% of resamples → statistical-utility disproof.
- Proof generation time >60s/record at N=10,000 (impractical for registry-scale deployment) → scalability disproof.
- Real-pilot (step 10) shows CTSS-exposure association direction reversal or non-replication vs. site-internal raw analysis → use-case disproof (biological, not cryptographic).
ROI Projection
- Direct: licensable privacy-infrastructure IP (ZK circuit library for geospatial health-data predicates) applicable beyond MS to any exposure-disease research (cancer clusters, environmental toxicology, infectious disease).
- Platform value: could underpin a federated-research-as-a-service product for pharma/CRO multi-site trials requiring geographic eligibility verification (e.g., "within 10km of trial site") without PHI exposure — addressable market includes clinical trial recruitment compliance tooling (est. $50–150M niche market).
- Regulatory value: potential fast-track alignment with GDPR/HIPAA "privacy by design" mandates, reducing legal/compliance overhead for multi-national MS consortia (e.g., MSBase, iConquerMS).
- Biological upside (contingent, not validated here): if CTSS/DNMT1/ZNF740 targets independently validate, this infrastructure directly accelerates their clinical biomarker/trial-site epidemiology studies.
TIME_TO_RESULT_DAYS: 60 (For the minimum viable synthetic-only cryptographic + statistical fidelity benchmark. Full validation including real-site pilot and audit: ~365 days.)
Implementation Sketch
# --- Circuit definition (circom-like pseudocode) --- template RegionMembership() { signal input lat; // private signal input lon; // private signal input region_id; // public signal input region_center_lat; // public signal input region_center_lon; // public signal input radius_km; // public signal output valid; dist <== haversine(lat, lon, region_center_lat, region_center_lon); valid <== LessThan(dist, radius_km); } # --- Client side (per patient) --- def generate_proof(true_lat, true_lon, region): witness = {lat: true_lat, lon: true_lon, region_id: region.id, ...} proof = snark_prove(circuit=RegionMembership, witness=witness) return proof, region.id # coordinates never leave client # --- Federated aggregation server --- def ingest_record(proof, region_id, ctss_value, covariates): assert snark_verify(proof, public_inputs=region_id) db.insert(region_id, ctss_value, covariates) # no raw coords stored def run_analysis(): df = db.fetch_all() # only region_id + expression + covariates model = mixedlm("ctss_value ~ exposure_index(region_id) + covariates", groups=df.region_id) return model.fit() # --- Adversarial fuzz harness --- for trial in range(10000): fake_coords = perturb_outside_region(true_coords, region) proof = attempt_forge_proof(fake_coords, region) assert not snark_verify(proof) # must fail # --- Privacy attack harness --- train_membership_inference_classifier(proof_transcripts, auxiliary_metadata) measure_AUC_vs_baseline()
- After circuit design (Day 10): if constraint count exceeds 10^6 or proving time exceeds 30s/record in initial benchmark → abort/redesign before full-scale build.
- After adversarial fuzzing (Day 25): if soundness failure rate >10^-3 → abort, do not proceed to statistical fidelity testing.
- After privacy attack simulation (Day 35): if reconstruction AUC >0.65 → abort, protocol fundamentally leaky.
- After statistical fidelity comparison (Day 45): if relative error >20% → abort real-pilot planning, redesign region-binning strategy.
- Before real-site IRB pilot (Day 60): require independent cryptographic audit sign-off; if audit identifies critical vulnerability → abort real-data phase indefinitely.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: false